Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases

ABSTRACT

Cyclic amino derivatives of formula (1) are described: (1) wherein: m and n, which may be the same or different, is each zero or the integer 1 or 2; Alk 3  is a covalent bond or a straight or branched C 1-6  alkylene chain; R 1  and R 2 , which may be the same or different, is each a hydrogen atom or a straight or branched C 1-6  alkyl group; D is an optionally substituted aromatic or heteroaromatic group; E is an optionally substituted C 7-10  cycloalkyl, C 7-10  cycloalkenyl or C 7-10  polycycloaliphatic group; and the salts, solvates, hydrates, tautomers or N-oxides thereof. The compounds are potent and selective modulators of the interaction between CXCR3 and its chemokine ligands and are thus of use in medicine, for example in the prevention or treatment of conditions involving inappropriate T-cell trafficking such as certain inflammatory, autoimmune and immunoregulatory disorders as described hereinafter.

This invention relates to a series of cyclic amino derivatives, tocompositions containing them, to processes for their preparation, and totheir use in medicine.

Over the last few years it has become increasingly clear that chemokines(chemotactic cytokines) play a key role in the recruitment andactivation of a variety of cell types in inflammatory processes, forexample recruitment of eosinophils in the tissue eosinophilia that is afeature of a number of pathological conditions including asthma,rhinitis, eczema and parasitic infections. Further certain chemokineshave been implicated in a variety of autoimmune diseases, such asrheumatoid arthritis, irritable bowel disease and multiple sclerosis aswell as playing a critical role in the pathway of viral infection, suchas invasion by HIV. [Schwarz, M. K. and Wells, T. N. C., Curr. Opin.Chem. Biol., 1999, 3, 407-17; Bousquet, J. et al, N. Eng. J. Med., 1990,323, 1033-39; Kay, A. B. and Corrigan, C. J., Br. Med. Bull., 1992, 48,51-64].

Chemokines are released by a wide variety of cells to attract andactivate, among other cell types, macrophages, T and B lymphocytes,eosinophils, basophils and neutrophils [Luster, New Eng. J. Med., 1998,338, 436-45; Rollins, Blood, 1997, 90, 909-28]. To date almost 40 humanchemokines have been well characterised [Schwarz, M. K., ibid; Wells, T.N. C. et al, Trends Pharmacol Sci, 1998, 19, 376-380] and they have beenclassified into two major classes, CXC and CC, depending on whether thefirst two cysteines in the amino acid sequence are separated by a singleamino acid (CXC) or are adjacent (CC). Members of two additionalclasses, C chemokines (lymphotactin-1 and lymphotactin-2) and a CX3Cchemokine (fractalkine) have also been identified. It was initiallythought that CXC chemokines, such as IL-8 (a neutrophil attractant),were associated with acute inflammation whilst CC chemokines wereassociated with chronic inflammatory diseases such as asthma, arthritisand atherosclerosis. However it is now known that members of bothclasses are involved in both chronic and acute inflammation.

In general the CXC chemokines, such as interleukin-8 (IL-8),neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatoryactivating protein (MGSA) are chemotactic primarily for neutrophils andT lymphocytes, whereas CC chemokines such as RANTES(regulation-upon-activation, normal T-cell expressed and secreted),MIP-1α, MIP-1β, the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3,MCP-4, MCP-5) and the eotaxins (-1,-2 and -3) are chemotactic formacrophages, T lymphocytes, eosinophils, dendritic cells and basophils.

The chemokines bind to specific cell-surface receptors. Seventeenmammalian receptors have been reported to date [Schwarz, M. K. ibid],all of which are seven-transmembrane-spanning G-protein coupledreceptors. The ligand binding characteristics of these receptors hasbeen identified, for example the ligands for CCR-1 are RANTES, MIP-1αand MCP-3 whilst those for CCR-2 are MCP-1, 2, 3, 4 and 5.

Chemokines and their receptors have been implicated as importantmediators of inflammatory, infectious, and immunoregulatory diseases, aswell as autoimmune pathologies such as rheumatoid arthritis andatherosclerosis.

The CXCR3 chemokine receptor is expressed primarily in T lymphocytes,and its functional activity can be measured by cytocolic calciumelevation or chemotaxis. The receptor was previously referred to as GPR9or CKR-L2. Its chromosomal location is unusual among the chemokinereceptors in being localised to Xq13. Ligands that have been identifiedthat are selective and are of high affinity are the CXC chemokines,interferon-gamma inducible protein (IP10), monokine induced byinterferon-gamma (MIG) and interferon-inducible T cell alphachemoattractant (ITAC).

The highly selective expression of CXCR3 makes it an ideal target forthe intervention to interrupt inappropriate T cell trafficking. Theclinical indications for such intervention are in T-cell mediateddiseases such as multiple sclerosis, rheumatoid arthritis and type Idiabetes. Inappropriate T-cell infiltration also occurs in psoriasis andother pathogenic skin inflammation conditions, although the diseases maynot be true autoimmune disorders. In this regard, up-regulation of IP-10expression in keratinocytes is a common feature in cutaneousimmunopathologies. Inhibition of CXCR3 can be beneficial in reducingrejection in organ transplantation. Ectopic expression of CXCR3 incertain tumours, especially subsets of B-cell malignancies indicate thatselective inhibitors of CXCR3 will have value in tumour immunotherapy,particularly attenuation of metastasis. [See, for example, Qin S. et al,J. Clin. Invest, 1998, 101, 746-754; Sørenson T. L. et al, J. Clin.Invest, 1999, 103, 807-815.]

Accordingly in view of the clinical importance of CXCR3 there is a greatneed for new therapeutic agents that modulate CXCR3 function. We havefound a class of cyclic amino derivatives that are potent and selectivemodulators of the interaction between CXCR3 and its chemokine ligands.Selective modulation of this interaction can be expected to have abeneficial effect and the compounds are thus of use in medicine, forexample in the prevention or treatment of conditions involvinginappropriate T-cell trafficking such as certain inflammatory,autoimmune and immunoregulatory disorders as described hereinafter.

International Patent Applications WO 01-14333, WO 00-76973, WO 00-76513,WO 00-76511, WO 00-76512, WO 00-76514, WO 00-76972 and European Patentspecification no. 916668 all generally disclose classes of substitutedpiperidine derivatives for use in modulating chemokine receptor activityin general.

International Patent Application WO 02-16353 discloses a class ofbicyclic heteroaromatic derivatives as inhibitors of the interactionbetween CCR3 and its chemokine ligands.

European Patent specification no. 625507 discloses a general class ofurea derivatives for use as ACAT inhibitors.

U.S. Pat. No. 3,424,761 discloses a class of 3-ureidopyrrolidinescharacterised by analgetic, central nervous system andpsychopharmacologic activities.

U.S. Pat. No. 6,329,395 discloses a general class of ureas for use asneuropeptide Y5 receptor antagonists.

Thus according to the first aspect of the invention we provide acompound of formula (1):

wherein:

-   -   m and n, which may be the same or different, is each zero or the        integer 1 or 2;    -   Alk³ is a covalent bond or a straight or branched C₁₋₆ alkylene        chain;    -   R¹ and R², which may be the same or different, is each a        hydrogen atom or a straight or branched C₁₋₆ alkyl group;    -   D is an optionally substituted aromatic or heteroaromatic group;    -   E is an optionally substituted C₇₋₁₀ cycloalkyl, C₇₋₁₀        cycloalkenyl or C₇₋₁₀ polycycloaliphatic group;    -   and the salts, solvates, hydrates, tautomers or N-oxides        thereof.

It will be appreciated that certain compounds of formula (1) may existas geometric isomers (E or Z isomers) The compounds may also have one ormore chiral centres, and exist as enantiomers or diastereomers. Theinvention is to be understood to extend to all such geometric isomers,enantiomers, diastereomers and mixtures thereof, including racemates.Formula (1) and the formulae hereinafter are intended to represent allindividual isomers and mixtures thereof, unless stated or shownotherwise. In addition, compounds of formula (1) may exist as tautomers,for example urea (—NHC(O)NH—)—(—NC(OH)NH—) tautomers. Formula (1) andthe formulae hereinafter are intended to represent all individualtautomers and mixtures thereof, unless stated otherwise.

It will also be appreciated that where desired the compounds of theinvention may be administered in a pharmaceutically acceptable pro-drugform, for example, as a protected carboxylic acid derivative, e.g. as aphysiologically acceptable ester. It will be further appreciated thatthe pro-drugs may be converted in vivo to the active compounds offormula (1), and the invention is intended to extend to such pro-drugs.Such pro-drugs are well known in the literature, see for exampleInternational Patent Application No. WO 00/23419, Bodor N. (AlfredBenson Symposium, 1982, 17, 156-177), Singh G. et al (J. Sci. Ind. Res.,1996, 55, 497-510) and Bundgaard H. (Design of Prodrugs, 1985, Elsevier,Amsterdam).

In the compounds of the invention and as represented by formula (1) andthe more detailed description hereinafter certain of the general termsused in relation to substituents are to be understood to include thefollowing atoms or groups unless specified otherwise.

Thus as used herein the term “alkyl”, whether present as a group or partof a group includes optionally substituted straight or branchedC₁₋₁₀alkyl groups, for example C₁₋₆alkyl groups such as methyl, ethyl,n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl or neopentylgroups. Optional substituents when present on these groups include thoseoptional substituents mentioned hereinafter.

The term “alkylene chain” is intended to include the alkyl groups asjust described in which a terminal hydrogen atom is replaced by acovalent bond to give a divalent chain. Examples include optionallysubstituted C₁₋₆ alkylene chains such as —CH₂—, —CH₂CH₂—, —CH(CH₃)CH₂—,—(CH₂)₂CH₂—, —(CH₂)₃CH₂—, —CH(CH₃)(CH₂)₂CH₂—, —CH₂CH(CH₃)CH₂—,—C(CH₃)₂—, —C(CH₃)₂CH₂—, —CH₂C(CH₃)₂CH₂—, —(CH₂)₂CH(CH₃)CH₂—,—CH(CH₃)CH₂CH₂—, —CH(CH₃)CH₂CH(CH₃)CH₂—, —CH₂CH(CH₃)CH₂CH₂—,—(CH₂)₂C(CH₃)₂CH₂—, —(CH₂)₄CH₂— or —(CH₂)₅CH₂—. Optional substituentswhen present on these groups include those optional substituentsmentioned hereinafter for alkyl groups.

In the compounds of the invention the cycloalkyl and cycloalkenyl groupsrepresented by E include non-aromatic cyclic or multicyclic, saturatedor partially saturated C₇₋₁₀ cycloalkyl or C₇₋₁₀ cycloalkenyl ringsystems. Where appropriate the cycloalkyl and cycloalkenyl groups may besubstituted with one or more substituents as described hereinafter.

The C₇₋₁₀ polycycloaliphatic groups represented by E include optionallysubstituted C₇₋₁₀bi- or tricycloalkyl or C₇₋₁₀bi- or tricycloalkenylgroups.

Examples of groups represented by E include, but are not limited to,optionally substituted cyclooctyl, cyclononyl, cyclodecyl, cyclohexenyl,cycloheptenyl, cyclooctenyl, adamantyl, adamantanonyl, noradamantyl,bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]heptenyl, bicyclo[3.1.1]heptanyl,bicyclo[3.1.1]heptenyl, bicyclo[2.2.2]octanyl, bicyclo[2.2.2]octenyl,bicyclo[3.2.1]octanyl, bicyclo[3.2.1]octenyl, bicyclo[3.3.1]nonanyl,bicyclo[6.2.0]decanyl, octahydro-4,7-methanoindenyl oroctahydronaphthalenyl.

Optional substituents which may be present on the group E include one,two, three or more substituents, which each may be the same ordifferent, selected from oxo, alkoxy, haloalkyl e.g. —CF₃, —CF₂H,haloalkoxy e.g. —OCF₂H, hydroxy (—OH), thiol (—SH), alkylthio, —CN,—CO₂H, —CO₂R^(9a) (where R^(9a) is an optionally substituted C₁₋₆alkylgroup), —SO₃H, —SOR^(10a) (where R^(10a) is a C₁₋₆ alkyl group) —SO₂R¹⁰,—SO₃R¹⁰, —OCO₂R¹⁰, —C(O)H, —C(O)R¹⁰, —OC(O)R¹⁰, —C(S)R¹⁰,—C(O)N(R^(11a))(R^(12a)) (where R^(11a) and R^(12a), which may be thesame or different is each a hydrogen atom or a C₁₋₆alkyl group),—N(R^(11a))C(O)R^(12a), —CSN(R^(11a))(R^(12a)),—N(R^(11a))C(S)(R^(12a)), —SO₂N(R^(11a))(R^(12a)),—N(R^(11a))SO₂R^(12a), —N(R^(11a))C(O)N(R^(12a))(R^(13a)) (where R^(13a)is a hydrogen atom or a C₁₋₆ alkylgroup),—N(R^(11a))C(S)N(R^(12a))(R^(13a)), N(R^(11a))SO₂N(R^(12a))(R^(13a)), oran optionally substituted cycloaliphatic, heterocycloaliphatic, aromaticor heteroaromatic group or a straight or branched C₁₋₆ alkyl or C₂₋₆alkenyl group optionally substituted by one, two, three or more of thesame or different halogen atoms, or alkoxy, haloalkyl, haloalkoxy,hydroxy (—OH), thiol (—SH), alkylthio, amino(-NH₂), substituted amino,optionally substituted C₆₋₁₂arylamino, —CN, —CO₂H, —CO₂R^(9a), —SO₃H,—SOR^(10a), —SO₂R¹⁰, —SO₃R¹⁰, —OCO₂R¹⁰, —C(O)H, —C(O)R¹⁰, —OC(O)R¹⁰,—C(S)R¹⁰, —C(O)N(R^(11a))(R^(12a)), —N(R^(11a))C(O)R^(12a),—CSN(R^(11a))(R^(12a)), —N(R^(11a))C(S)(R^(12a)),—SO₂N(R^(11a))(R^(12a)), —N(R^(11a))SO₂N(R^(12a))(R^(13a)),—N(R^(11a))C(O)N(R^(12a))(R^(13a))—, —N(R^(11a))SO₂R^(12a),—N(R^(11a))C(S)N(R^(12a))(R^(13a)), or optionally substitutedcycloaliphatic, heterocycloaliphatic, aromatic or heteroaromatic groups.

In general in the compounds of formula (1) the term “cycloaliphaticgroup” includes optionally substituted non-aromatic cyclic ormulticyclic, saturated or partially saturated C₃₋₁₀ ring systems, suchas, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclooctyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl,cyclooctenyl, adamantyl, norbornyl, norbornenyl, bicyclo[2.2.1]heptanylor bicyclo[2.2.1]heptenyl. Particular examples include optionallysubstituted C₃₋₆ cycloalkyl ring systems such as cyclopropyl,cyclobutyl, cyclopentyl and cyclohexyl groups. Optional substituentspresent on these groups include those substituents mentionedhereinafter.

The term “heterocycloaliphatic group” refers to an optionallysubstituted non-aromatic 3 to 10 membered saturated or partiallysaturated monocyclic or multicyclic hydrocarbon ring system containingone, two, three or four L³ linker atoms or groups. Particular examplesof suitable L³ atoms or groups include —O— or —S— atoms or —C(O)—,—C(O)O—, —OC(O)—, —C(S)—, —S(O)—, —S(O)₂—, —N(R¹⁴)— [where R¹⁴ is ahydrogen atom or a C₁₋₆ alkyl group], —N(R¹⁴)N(R¹⁴), —N(R¹⁴)O,—ON(R¹⁴)—, —CON(R¹⁴)—, —OC(O)N(R¹⁴)—, —CSN(R¹⁴)—, —N(R¹⁴)CO—,—N(R¹⁴)C(O)O—, —N(R¹⁴)CS—, —S(O)₂N(R¹⁴)—, —N(R¹⁴)S(O)₂—,—N(R¹⁴)CON(R¹⁴)—, —N(R¹⁴)CSN(R¹⁴)—, —N(R¹⁴)SO₂N(R¹⁴)— groups. Where thelinker group contains two R¹⁴ substituents, these may be the same ordifferent. Optional substituents present on the heterocycloaliphaticgroups include those substituents mentioned hereinafter.

Particular examples of heterocycloaliphatic groups include optionallysubstituted cyclobutanonyl, cyclopentanonyl, cyclohexanonyl, azetidinyl,tetrahydrofuranyl, tetrahydropyranyl, pyrrolinyl, e.g. 2- or3-pyrrolinyl, pyrrolidinyl, pyrrolidinonyl, oxazolidinyl,oxazolidinonyl, dioxolanyl, e.g. 1,3-dioxolanyl, imidazolinyl, e.g.2-imidazolinyl, imidazolidinyl, pyrazolinyl, e.g. 2-pyrazolinyl,pyrazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, e.g. 2- or4-pyranyl, pyranonyl, piperidinyl, piperidinonyl, quinuclidinyl,1,4-dioxanyl, morpholinyl, morpholinonyl, 1,4-dithianyl,thiomorpholinyl, piperazinyl, N—C₁₋₆ alkylpiperazinyl, homopiperazinyl,dihydrofuran-2-onyl, tetrahydropyran-2-onyl, isothiazolidinyl1,1-dioxide, [1,2]thiazinanyl 1,1-dioxide, tetrahydrothiophenyl,tetrahydrothiopyranyl, pyrazolidin-3-onyl, tetrahydrothiopyranyl1,1-dioxide, tetrahydrothiophenyl 1,1-dioxide, 1,3,5-trithianyl,oxazinyl, e.g. 2H-1,3-, 6H-1,3-, 6H-1,2-, 2H-1,2- or 4H-1,4-oxazinyl,1,2,5-oxathiazinyl, isoxazinyl, e.g. o- or p-isoxazinyl, oxathiazinyl,e.g. 1,2,5 or 1,2,6-oxathiazinyl, or 1,3,5,-oxadiazinyl groups.

The optional substituents which may be present on the alkyl,cycloaliphatic or heterocycloaliphatic groups described above, includeone, two, three or more substituents, which each may be the same ordifferent, selected from halogen atoms, or alkoxy, haloalkyl,haloalkoxy, hydroxy (—OH), thiol (—SH), alkylthio, amino(-NH₂),substituted amino, optionally substituted C₆₋₁₂arylamino, —CN, —CO₂H,—CO₂R⁹ (where R⁹ is an optionally substituted C₁₋₆ alkyl group), —SO₃H,—SOR¹⁰ (where R¹⁰ is a C₁₋₆ alkyl group) —SO₂R¹⁰, —SO₃R¹⁰, —OCO₂R¹⁰,—C(O)H, —C(O)R¹⁰, —OC(O)R¹⁰, —C(S)R¹⁰, —C(O)N(R¹¹)(R¹²) (where R¹¹ andR¹², which may be the same or different is each a hydrogen atom or aC₁₋₆ alkyl group), —OC(O)N(R¹¹)(R¹²), N(R¹¹)C(O)R¹², —CSN(R¹¹)(R¹²),—N(R¹¹)C(S)(R¹²), —SO₂N(R¹¹)(R¹²), —N(R¹¹)SO₂R¹², —N(R¹¹)C(O)N(R¹²)(R¹³)(where R¹³ is a hydrogen atom or a C₁₋₆ alkyl group),—N(R¹¹)C(S)N(R¹²)(R¹³), —N(R¹¹)SO₂N(R¹²)(R¹³), or optionally substitutedaromatic or heteroaromatic groups or a C₁₋₆ alkyl group optionallysubstituted by one, two, three or more of the same or different atoms orgroups selected from halogen atoms, or alkoxy, haloalkyl, haloalkoxy,hydroxy, thiol, alkylthio, amino, substituted amino, optionallysubstituted C₆₋₁₂arylamino, —CN, —CO₂H, —CO₂R⁹, —SO₃H, —SOR¹⁰, —SO₂R¹⁰,—SO₃R¹⁰, —OCO₂R¹⁰, —C(O)H, —C(O)R¹⁰, —OC(O)R¹⁰, —C(S)R¹⁰,—C(O)N(R¹¹)(R¹²), —OC(O)N(R¹¹)(R¹²), —N(R¹¹)C(O)R¹², —CSN(R¹¹)(R¹²),—N(R¹¹)C(S)(R¹²), —SO₂N(R¹¹)(R¹²), —N(R¹¹)SO₂R¹²,—N(R¹¹)C(O)N(R¹²)(R¹³), —N(R¹¹)C(S)N(R¹²)(R¹³), —N(R¹¹)SO₂N(R¹²)(R¹³),or an optionally substituted aromatic or heteroaromatic groups.Substituted amino groups include —NHR¹⁰ and —N(R¹⁰)(R¹¹) groups.

Cycloaliphatic groups may be linked to the remainder of the compound offormula (1) by any available ring carbon atom. Heterocycloaliphaticgroups may be linked to the remainder of the compound of formula (1) byany available ring carbon or, where available, ring nitrogen atom.

The term “halogen atom” is intended to include fluorine, chlorine,bromine or iodine atoms.

The term “haloalkyl” is intended to include the alkyl groups justmentioned substituted by one, two or three of the halogen atoms justdescribed. Particular examples of such groups include —CF₃, —CCl₃,—CHF₂, —CHCl₂, —CH₂F, and —CH₂Cl groups.

The term “alkoxy” as used herein is intended to include straight orbranched C₁₋₁₀alkoxy for example C₁₋₆alkoxy such as methoxy, ethoxy,n-propoxy, i-propoxy and t-butoxy. “Haloalkoxy” as used herein includesany of those alkoxy groups substituted by one, two or three halogenatoms as described above. Particular examples include —OCF₃, —OCCl₃,—OCHF₂, —OCHCl₂, —OCH₂F and —OCH₂Cl groups.

As used herein the term “alkylthio” is intended to include straight orbranched C₁₋₁₀alkylthio, e.g. C₁₋₆alkylthio such as methylthio orethylthio groups.

The terms “aromatic group” and “aryl group” are intended to include forexample optionally substituted monocyclic ring C₆₋₁₂ aromatic groups,such as phenyl, or bicyclic fused ring C₆₋₁₂ aromatic groups, such as,1- or 2-naphthyl groups.

The terms “heteroaromatic group” and “heteroaryl group” are intended toinclude for example optionally substituted C₁₋₉ heteroaromatic groupscontaining for example one, two, three or four heteroatoms selected fromoxygen, sulfur or nitrogen atoms (or oxidised versions thereof). Ingeneral, the heteroaromatic groups may be for example monocyclic orbicyclic fused ring heteroaromatic groups. Monocyclic heteroaromaticgroups include for example five- or six-membered heteroaromatic groupscontaining one, two, three or four heteroatoms selected from oxygen,sulfur or nitrogen atoms. Bicyclic heteroaromatic groups include forexample eight- to thirteen-membered fused-ring heteroaromatic groupscontaining one, two or more heteroatoms selected from oxygen, sulphur ornitrogen atoms.

Each of these aromatic or heteroaromatic groups may be optionallysubstituted by one, two, three or more R¹⁶ atoms or groups as definedbelow.

Particular examples of monocyclic ring heteroaromatic groups of thistype include pyrrolyl, furyl, thienyl, imidazolyl,N—C₁₋₆alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl,pyridazinyl, pyrazinyl, tetrazolyl, or triazinyl.

Particular examples of bicyclic ring heteroaromatic groups of this typeinclude benzofuryl, benzothienyl, benzotriazolyl, indolyl, indazolinyl,benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl,benzisoxazolyl, benzopyranyl, quinazolinyl, quinoxalinyl,naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl,pyrido[4,3-b]-pyridyl, quinolinyl, isoquinolinyl or phthalazinyl.

Optional substituents which may be present on the aromatic orheteroaromatic groups include one, two, three or more substituents, eachselected from an atom or group R¹⁶ in which R¹⁶ is —R_(16a) or-Alk⁴(R^(16a))_(f), where R^(16a) is a halogen atom, or an amino (—NH₂),substituted amino, nitro, cyano, hydroxyl (—OH), substituted hydroxyl,amidino, formyl, carboxyl (—CO₂H), esterified carboxyl, thiol (—SH),substituted thiol, —COR¹⁷ [where R¹⁷ is an -Alk⁴(R^(16a))_(f),heterocycloaliphatic, cycloaliphatic, aryl or heteroaryl group], —CSR¹⁷,—SO₃H, —SOR¹⁷, —SO₂R¹⁷, —SO₃R¹⁷, —SO₂NH₂, —SO₂NHR¹⁷, SO₂N(R¹⁷)₂, —CONH₂,—CSNH₂, —CONHR¹⁷, —CSNHR¹⁷, —CON(R¹⁷)₂, —CSN(R¹⁷)₂, —N(R¹⁸)SO₂R¹⁷,[where R¹⁸ is a hydrogen atom or a C₁₋₆ alkyl group] —N(SO₂R¹⁷)₂,—N(R¹⁸)SO₂NH₂, —N(R¹⁸)SO₂NHR¹⁷, —N(R¹⁷)SO₂N(R¹⁸)₂, —N(R¹⁸)COR¹⁷,—N(R¹⁸)CONH₂, —N(R¹⁸)CONHR¹⁷, —N(R¹⁸)CON(R¹⁷)₂, —N(R¹⁸)CSNH₂,—N(R¹⁸)CSNHR¹⁷, —N(R¹⁸)CSN(R¹⁷)₂, —N(R¹⁸)CSR¹⁷, —N(R¹⁸)C(O)OR¹⁷,—SO₂NHet¹ [where —NHet¹ is an optionally substitutedC₃₋₇heterocycloaliphatic group containing at least one N atom andoptionally containing one or more other —O— or —S— atoms or —N(R¹⁸)—,—C(O)— or —C(S)— groups], —CONHet¹, —CSNHet¹, —N(R¹⁴)SO₂NHet¹,—N(R¹⁸)CONHet¹, —N(R¹⁸)CSNHet¹, —SO₂N(R¹⁸)Het² [where Het² is anoptionally substituted monocyclic C₃₋₇ cycloalipatic group optionallycontaining one or more —O— or —S— atoms or —N(R¹⁸)—, —C(O)— or —C(S)—groups], -Het², —CON(R¹⁸)Het², —CSN(R¹⁸)Het², —N(R¹⁸)CON(R¹⁸)Het²,—N(R¹⁸)CSN(R¹⁸)Het², optionally substituted aryl or heteroaryl group;Alk⁴ is a straight or branched C₁₋₆alkylene, C₂₋₆alkenylene orC₂₋₆alkynylene chain, optionally interrupted by one, two or three —O— or—S— atoms or —S(O)_(g)— [where g is an integer 1 or 2] or —N(R¹⁸)—groups; and f is zero or an integer 1, 2 or 3. It will be appreciatedthat when two R¹⁷ or R¹⁸ groups are present in one of the abovesubstituents, the R¹⁷ or R¹⁸ groups may be the same or different.

When in the group -Alk⁴(R^(16a))_(f) f is an integer 1, 2 or 3, it is tobe understood that the substituent or substituents R^(16a) may bepresent on any suitable carbon atom in -Alk⁴. Where-more than oneR^(16a) substituent is present these may be the same or different andmay be present on the same or different atom in -Alk⁴. Clearly, when fis zero and no substituent R^(16a) is present the chain represented byAlk⁴ becomes a corresponding group.

When R^(16a) is a substituted amino group it may be for example a group—NHR¹⁷ [where R¹⁷ is as defined above] or a group —N(R17)₂ wherein eachR¹⁷ group is the same or different.

When R^(16a) is a substituted hydroxyl or substituted thiol group it maybe for example a group —OR¹⁷ or a —SR¹⁷ group respectively.

Esterified carboxyl groups represented by the group R^(16a) includegroups of formula —CO₂Alk⁵ wherein Alk⁵ is an optionally substitutedalkyl group.

When Alk⁴ is present in or as a substituent it may be for example amethylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene,s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene,3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylenechain, optionally interrupted by one, two, or three —O— or —S—, atoms or—S(O)—, —S(O)₂— or —N(R¹⁵)— groups.

When —NHet¹ or -Het² forms part of a substituent R¹⁶ each may be forexample an optionally substituted 2- or 3-pyrrolinyl, pyrrolidinyl,pyrazolinyl, pyrazolidinyl, piperazinyl, imidazolinyl, imidazolidinyl,morpholinyl, thiomorpholinyl, piperidinyl, oxazolidinyl or thiazolidinylgroup. Additionally Het² may represent for example, an optionallysubstituted cyclopentyl or cyclohexyl group. Optional substituents whichmay be present on —NHet¹ or -Het² include those substituents describedabove in relation to aromatic groups.

Particularly useful atoms or groups represented by R¹⁶ include fluorine,chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl, ethyl,n-propyl, i-propyl, n-butyl or t-butyl, optionally substituted phenyl,pyridyl, pyrimidinyl, pyrrolyl, furyl, thiazolyl, thienyl, morpholinyl,thiomorpholinyl, piperazinyl, pyrrolidinyl or piperidinyl,C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, carboxyC₁₋₆alkyl,e.g. carboxyethyl, C₁₋₆alkylthio e.g. methylthio or ethylthio,carboxyC₁₋₆alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or3-carboxyproplthio, C₁₋₆alkoxy, e.g. methoxy or ethoxy,hydroxyC₁₋₆alkoxy, e.g. 2-hydroxyethoxy, optionally substituted phenoxy,pyridyloxy, thiazolyoxy, phenylthio or pyridylthio, C₅₋₇cycloalkoxy,e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl,haloC₁₋₆alkoxy, e.g. trifluoromethoxy, C₁₋₆alkylamino, e.g. methylaminoor ethylamino, amino (—NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl oraminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino,aminoC₁₋₆alkylamino e.g. aminoethylamino, Het¹NC₁₋₆alkylamino e.g.morpholinopropylamino, C₁₋₆alkylaminoC₁₋₆alkyl, e.g. ethylaminoethyl,C₁₋₆ dialkylaminoC₁₋₆alkyl, e.g. diethylaminoethyl, aminoC₁₋₆alkoxy,e.g. aminoethoxy, C₁₋₆alkylaminoC₁₋₆alkoxy, e.g. methylaminoethoxy, C₁₋₆dialkylaminoC₁₋₆alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy,diisopropylaminoethoxy, or dimethylaminopropoxy, hydroxyC₁₋₆alkylaminoe.g. hydroxyethylamino, imido, such as phthalimido or naphthalimido,e.g. 1,8-naphthalimido, nitro, cyano, amidino, formyl[HC(O)—], carboxyl(—CO₂H), —CO₂Alk⁵ [where Alk⁵ is as defined above], C₁₋₆alkanoyl e.g.acetyl, optionally substituted benzoyl, thiol (—SH), thioC₁₋₆alkyl, e.g.thiomethyl or thioethyl, —SC(═NH)NH₂, sulphonyl (—SO₃H), —SO₃R¹⁸,C₁₋₆alkylsulphinyl e.g. methylsulphinyl, C₁₋₆alkylsulphonyl, e.g.methylsulphonyl, aminosulphonyl (—SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g.methylamino-sulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl,e.g. dimethyl-aminosulphonyl or diethylaminosulphonyl, optionallysubstituted phenylamino-sulphonyl, carboxamido (—CONH₂),C₁₋₆alkylaminocarbonyl, e.g. methylamino-carbonyl or ethylaminocarbonyl,C₁₋₆dialkylaminocarbonyl, e.g. dimethyl-aminocarbonyl ordiethylaminocarbonyl, aminoC₁₋₆alkylaminocarbonyl, e.g.aminoethylaminocarbonyl, C₁₋₆dialkylaminoC₁₋₆alkylaminocarbonyl, e.g.diethylaminoethylaminocarbonyl, aminocarbonylamino,C₁₋₆alkylamino-carbonylamino, e.g. methylaminocarbonylamino orethylaminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g.dimethylaminocarbonylamino or diethyl-aminocarbonylamino,C₁₋₆alkylaminocabonylC₁₋₆alkylamino, e.g.methylamino-carbonylmethylamino, aminothiocarbonylamino,C₁₋₆alkylaminothiocarbonyl-amino, e.g. methylaminothiocarbonylamino orethylaminothiocarbonylamino, C₁₋₆dialkylaminothiocarbonylamino, e.g.dimethylaminothiocarbonylamino or diethylaminothiocarbonylamino,C₁₋₆alkylaminothiocarbonylC₁₋₆alkylamino, e.g.ethylaminothiocarbonylmethylamino, —CONHC(═NH)NH₂,C₁₋₆alkyl-sulphonylamino, e.g. methylsulphonylamino orethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g.dimethylsulphonylamino or diethylsulphonyl-amino, optionally substitutedphenylsulphonylamino, aminosulphonylamino (—NHSO₂NH₂),C₁₋₆alkylaminosulphonylamino e.g. methylaminosulphonylamino orethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g.dimethylaminosulphonylamino or diethylaminosulphonylamino, optionallysubstituted morpholinesulphonylamino ormorpholinesulphonylC₁₋₆alkylamino, optionally substitutedphenylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetylamino,aminoC₁₋₆alkanoylamino e.g. aminoacetylamino,C₁₋₆dialkyl-aminoC₁₋₆alkanoylamino, e.g. dimethylaminoacetylamino,C₁₋₆alkanoyl-aminoC₁₋₆alkyl, e.g. acetylaminomethyl,C₁₋₆alkanoylaminoC₁₋₆alkylamino, e.g. acetamidoethylamino,C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylaminoor t-butoxycarbonylamino or optionally substituted benzyloxy,benzylamino, pyridylmethoxy, thiazolylmethoxy, benzyloxy-carbonylamino,benzyloxycarbonylaminoC₁₋₆alkyl e.g. benzyloxycarbonyl-aminoethyl,thiobenzyl, pyridylmethylthio or thiazolylmethylthio groups.

Where desired, two adjacent R¹⁶ substituents may be linked together toform a cyclic group such as a cyclic ether, e.g. a C₁₋₆alkylenedioxygroup such as methylenedioxy or ethylenedioxy or a C₃₋₆ cycloalkyl or3-10 membered monocylic heterocycloaliphatic group as defined herein.

It will be appreciated that where two or more R¹⁶ substituents arepresent, these need not necessarily be the same atoms and/or groups. Ingeneral, the substituent(s) may be present at any available ringposition in the aromatic or heteroaromatic group.

When R¹⁰, R^(10a), R¹¹, R^(11a), R¹², R^(12a), R¹³, R^(13a), R¹⁴ or R¹⁸is present as a C₁₋₆alkyl group it may be a straight or branched C₁₋₆alkyl group e.g. a C₁₋₃ alkyl group such as methyl, ethyl or i-propyl.

Examples of optionally substituted alkyl groups present in ester groupsof formulae —CO₂R⁹, —CO₂R^(9a) and —CO₂Alk⁵ include C₁₋₆ alkyl groups asherein described. Optional substituents which may be present on thesealkyl groups include optionally substituted cycloaliphatic, aromatic orheteroaromatic groups as herein defined.

The presence of certain substituents in the compounds of formula (1) mayenable salts of the compounds to be formed. Suitable salts includepharmaceutically acceptable salts, for example acid addition saltsderived from inorganic or organic acids, and salts derived frominorganic and organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides,alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, orisothionates, arylsulphonates, e.g. p-toluenesulphonates, besylates ornapsylates, phosphates, sulphates, hydrogen sulphates, acetates,trifluoroacetates, propionates, citrates, maleates, fumarates,malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts derived from inorganic or organic bases include alkali metal saltssuch as sodium or potassium salts, alkaline earth metal salts such asmagnesium or calcium salts, and organic amine salts such as morpholine,piperidine, dimethylamine or diethylamine salts.

Particularly useful salts of compounds according to the inventioninclude pharmaceutically acceptable salts, especially acid additionpharmaceutically acceptable salts.

Alk³ in one group of compounds of formula (1) is preferably a C₁₋₃alkylene chain, in particular —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—, moreparticularly —CH₂—.

Alternatively Alk³ in another group of compounds of formula (1) is acovalent bond.

In compounds of formula (1) m and n, which may be the same or different,is each in particular zero or the integer 1. In particular m and n iseach the integer 1.

R¹ and R², which may be the same or different, is each preferably ahydrogen atom or a straight or branched C₁₋₃ alkyl group, especiallymethyl. In one particular group of compounds of the invention R¹ and R²is each a hydrogen atom.

One group of compounds of the invention has the formula (1) wherein D isselected from optionally substituted phenyl, 1- or 2-naphthyl, pyrrolyl,furyl, thienyl, imidazolyl, N—C₁₋₆alkylimidazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, pyrazolyl, triazolyl, oxadiazolyl,thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, tetrazolyl,triazinyl, benzofuryl, benzothienyl, benzotriazolyl, indolyl,indazolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl,benzisoxazolyl, benzopyranyl, quinazolinyl, quinoxalinyl,naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl,pyrido[4,3-b]-pyridyl, quinolinyl or isoquinolinyl.

More particular D groups include optionally substituted phenyl, 1- or2-naphthyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, benzofuryl,benzothienyl, indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl,benzisoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, quinolinylor isoquinolinyl. D may also in particular be an optionally substitutedpyrrolyl, furyl, thienyl, imidazolyl, N—C₁₋₆alkylimidazolyl, oxazolyl,isoxazolyl, thiazolyl or isothiazolyl group.

In one group of compounds of formula (1) D is especially an optionallysubstituted phenyl or 2-naphthyl group. D is also especially anoptionally substituted thienyl group.

Particular substituents, which may be present on the group D, are one,two, three or more atoms or groups selected from fluorine, chlorine,bromine, optionally substituted straight or branched C₁₋₃ alkyl (whereinthe optional alkyl substituent is in particular an optionallysubstituted phenyl or monocyclic heteroaryl group, especially pyridyl,pyrimidinyl, pyrrolyl, furyl, thiazolyl or thienyl), optionallysubstituted phenyl, monocyclic heteroaryl, morpholinyl, thiomorpholinyl,piperazinyl, pyrrolidinyl, piperidinyl, methoxy, phenoxy, pyridyloxy,benzoyl, pyridoyl or COCH₃, OCF₃, OCF₂H, CF₃, NO₂, NH₂, NHCH₃, N(CH₃)₂,CONH₂, CONHCH₃, CON(CH₃)₂, CO₂CH₃, CO₂CH₂CH_(CH) ₃, CO₂H or —CN, —SCH₃,—SCH₂CH₃, —SO₂CH₃ or two adjacent substituents are linked together toform methylenedioxy, ethylenedioxy or cyclopentyl. The monocyclicheteroaryl substituents in compounds of this type are in particularselected from pyridyl, pyrimidinyl, pyrrolyl, furyl, thiazolyl orthienyl.

More particular D substituents are selected from fluorine, chlorine,CF₃, methyl, ethyl, methoxy, OCF₂H, OCF₃ or optionally substitutedphenyl, monocyclic heteroaryl, especially pyridyl, pyrimidinyl,pyrrolyl, furyl, thiazolyl or thienyl, phenoxy or pyridyloxy or —SCH₃.Especially useful D substituents include fluorine, chlorine, CF₃,methyl, ethyl, methoxy, —SCH₃ or optionally substituted phenyl orphenoxy. The optional substituents which may in particular be present onthese aryl or heteroaryl groups are one, two, three or more atoms orgroups selected from fluorine, chlorine, bromine, straight or branchedC₁₋₃ alkyl, methoxy, OCF₃, OCF₂H, CF₃, CN, NO₂, NH₂, NHCH₃, N(CH₃)₂,CONH₂, CONHCH₃, CON(CH₃)₂, CO₂CH₃, CO₂CH₂CH₃ or CO₂H.

Particular examples of D groups include 3,4-dichlorobenzene, 3- or4-chlorobenzene or 3- or 4-trifluoromethylbenzene. D is also inparticular a group selected from 3,5-bistrifluoromethylbenzene,3-methylsulfanylbenzene or 5-phenylthien-2-yl.

One group of compounds has the formula (1) wherein E is selected fromoptionally substituted cycloheptyl, cyclooctyl, cyclononyl,cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantyl,bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]heptenyl, bicyclo[3.1.1]heptanylor bicyclo[3.1.1]heptenyl.

Particular substituents, which may be present on the group E, are one,two, three or more groups selected from hydroxy, or optionallysubstituted phenyl or monocyclic heteroaromatic, CONH₂, CONHCH₃,CON(CH₃)₂, CO₂CH₃, CO₂CH₂CH₃, CO₂H or optionally substituted straight orbranched C₁₋₆ alkyl or C₂₋₆ alkenyl, wherein the optional alkyl oralkenyl substituent is in particular an optionally substituted phenyl ormonocyclic heteroaromatic group. Particular examples of the optionallysubstituted C₁₋₆ alkyl or C₂₋₆ alkenyl groups are —CH₃, —CH₂CH₃,—CH(CH₃)₂, —(CH₂)₂CH₃, —(CH₂)₃CH₃, —CH(CH₃)CH₂CH₃, —CH₂CH(CH₃)₂,—CH₂C(CH₃)₃, —C(CH₃)₃, —(CH₂)₄CH₃, —(CH₂)₅CH₃ —CHCH₂, —CHCHCH₃,—CH₂CHCH₂, —CHCHCH₂CH₃, —CH₂CHCHCH₃, —(CH₂)₂CHCH₂ or —C(CH₂)CH₃.

One preferred group of compounds is where E is substituted with one,two, three or more methyl groups.

E in one particular group of compounds of the invention is a1-cyclooctenyl or 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl group. E isalso especially an adamantyl or cyclooctyl group.

One particular group of optional substituents which may be present oncycloaliphatic or heterocycloaliphatic groups in compounds of formula(1), in particular on the D or E group substituents, are one, two orthree groups selected from C₁₋₃ alkoxy, OCF₃, OCF₂H, CF₃, C₁₋₃alkylthio, —CN, NHCH₃, N(CH₃)₂, CONH₂, CONHCH₃, CON(CH₃)₂, CO₂CH₃,CO₂CH₂CH₃, —CO₂C(CH₃)₃, —COCH₃, —NHCOCH₃, —N(CH₃)COCH₃, CO₂H, oroptionally substituted straight or branched C₁₋₃ alkyl, wherein theoptional alkyl substituent is in particular —CN, C₁₋₃ alkoxy, NHCH₃,N(CH₃)₂, CONH₂, CONHCH₃, CON(CH₃)₂, CO₂CH₃, CO₂CH₂CH₃, —CO₂C(CH₃)₃,—COCH₃, —NHCOCH₃, —N(CH₃)COCH₃ or CO₂H.

Particular aromatic or heteroaromatic substituents, which may be presenton compounds of formula (1), in particular on the D or E groupsubstituents, are one, two or three atoms or groups selected fromfluorine, chlorine, bromine, straight or branched C₁₋₃ alkyl, methoxy,OCF₃, OCF₂H, CF₃, CN, No₂, NH₂, NHCH₃, N(CH₃)₂, CONH₂, CONHCH₃,CON(CH₃)₂, CO₂CH₃, CO₂CH₂CH₃ or CO₂H.

Particularly useful compounds of the invention include:

-   -   1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea;    -   1-[1-((E)-1-Cyclooct-1-enyl)methyl-piperidin-4-yl]-3-(4-trifluoromethylphenyl)-urea;    -   and the salts, solvates, hydrates, tautomers or N-oxides        thereof.

Other particularly useful compounds include:

-   -   N-2-Naphthyl-N′-(cyclooctene-1-yl)methylpiperidine urea;    -   1-[-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-naphthalen-2-yl        urea;    -   1-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-methyl-3-(3-trifluoromethylphenyl)urea;    -   1-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-methyl-3-naphthalen-2-yl        urea;    -   1-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-methyl-3-(3-methylsulfanylphenyl)urea;    -   1-(1-Adamantan-1-ylmethylpiperidin-4-yl)-3-(3-trifluoromethylphenyl)-urea;    -   1-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-ethyl-3-(3-methylsulfanylphenyl)urea;    -   ′3-{3-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)-piperidin-4-yl]ureido}benzoic        benzoic acid methyl ester;    -   ′1-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(5-phenylthiophen-2-yl)urea;    -   ′1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(5-phenylthiophen-2-yl)urea;    -   ′1-(4-Chloro-3-trifluoromethylphenyl)-3-[1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea;    -   ′1-(3,5-Bistrifluoromethylphenyl)-3-[1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea;    -   ′1-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(3-trifluoromethylphenyl)urea;    -   ′1-(4-Chloro-3-trifluoromethylphenyl)-3-[1-((E)-1-cyclooct-1-enyl)methyl-piperidine-4-yl]urea;    -   ′1-(3,5-Bistrifluoromethylphenyl)-3-[1-((E)-1-cyclooct-1-enyl)methyl-piperidin-4-yl]urea    -   ′1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3-ethylphenyl)urea;    -   and the salts, solvates, hydrates, tautomers or N-oxides        thereof.

Compounds according to the invention are potent and selective inhibitorsof chemokines binding to the CXCR3 receptor as demonstrated bydifferential inhibition of this receptor when compared to otherchemokine receptors, such as CCR3. The ability of the compounds to actin this way may be simply determined by employing tests such as thosedescribed in the Examples hereinafter.

The compounds are of use in modulating chemokine mediated cellsignalling and in particular are of use in the prophylaxis and/ortreatment of diseases or disorders involving inappropriate T-celltrafficking. The invention extends to such a use and to the use of thecompounds of formula (1) for the manufacture of a medicament fortreating such diseases and disorders. Particular diseases includeinflammatory, autoimmune and immunoregulatory disorders.

Particular uses to which the compounds of the invention may be putinclude: (1) inflammatory or allergic diseases such as systemicanaphylaxis or hypersensitivity responses, drug allergies, insect stingallergies; inflammatory bowel diseases, such as Crohn's disease,ulcerative colitis, ileitis and enteritis; vaginitis; psoriasis andinflammatory dermatoses such as dermatitis, eczema, atopic dermatitis,allergic contact dermatitis, urticaria; vasculitis;spondyloarthropathies; scieroderma; respiratory allergic diseases suchas asthma, allergic rhinitis, hypersensitivity lung diseases and thelike. (2) autoimmune diseases, such as arthritis (rheumatoid andpsoriatic), multiple sclerosis, systemic lupus erythematosus, diabetes,glomerulonephritis and the like. (3) graft rejection (includingallograft rejection and graft-v-host disease), and (4) other diseases inwhich undesired inflammatory responses are to be inhibited e.g.atherosclerosis, myositis, neurodegenerative diseases, Alzheimer'sdisease, encephalitis, meningitis, hepatitis, nephritis, sepsis,sarcoidosis, conjunctivitis, otitis, chronic obstructive pulmonarydisease, sinusitis, Behcet's syndrome, Sjorgen's syndrome andglomerulonephrites.

In a particular embodiment, the compounds of the present invention areuseful for the treatment of the aforementioned exemplary disordersirrespective of their etiology, for example, for the treatment ofmultiple sclerosis, psoriasis, rheumatoid arthritis, allograft rejectionand graft-v-host disease.

The compounds of formula (1) can be used alone or in combination withother compounds having related utilities to prevent and treatinflammatory and immunoregulatory disorders and diseases, includingasthma and allergic diseases, as well as autoimmune pathologies such asmultiple sclerosis, rheumatoid arthritis and atherosclerosis, and thosepathologies as discussed herein.

For the prophylaxis or treatment of disease the compounds according tothe invention may be administered as pharmaceutical compositions, andaccording to a further aspect of the invention we provide apharmaceutical composition which comprises a compound of formula (1)together with one or more pharmaceutically acceptable carriers,excipients or diluents.

Alternate compositions of this invention comprise a compound of formula(1) or a salt thereof; an additional agent selected from animmunosuppressant or an anti-inflammatory agent; and anypharmaceutically acceptable carrier, adjuvant or vehicle.

Pharmaceutical compositions according to the invention may take a formsuitable for oral, buccal, parenteral, nasal, topical, vaginal or rectaladministration, or a form suitable for administration by inhalation orinsufflation.

For oral administration, the pharmaceutical compositions may take theform of, for example, tablets, lozenges or capsules prepared byconventional means with pharmaceutically acceptable excipients such asbinding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidoneor hydroxypropyl methylcellulose); fillers (e.g. lactose,microcrystalline cellulose or calcium hydrogen phosphate); -lubricants(e.g. magnesium stearate, talc or silica); disintegrants (e.g. potatostarch or sodium glycollate); or wetting agents (e.g. sodium laurylsulphate). The tablets may be coated by methods well known in the art.Liquid preparations for oral administration may take the form of, forexample, solutions, syrups or suspensions, or they may be presented as adry product for constitution with water or other suitable vehicle beforeuse. Such liquid preparations may be prepared by conventional means withpharmaceutically acceptable additives such as suspending agents,emulsifying agents, non-aqueous vehicles and preservatives. Thepreparations may also contain buffer salts, flavouring, colouring andsweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to givecontrolled release of the active compound

For buccal administration the compositions may take the form of tabletsor lozenges formulated in conventional manner.

The compounds for formula (1) may be formulated for parenteraladministration by injection e.g. by bolus injection or infusion.Formulations for injection may be presented in unit dosage form, e.g. inglass ampoule or multi dose containers, e.g. glass vials. Thecompositions for injection may take such forms as suspensions, solutionsor emulsions in oily or aqueous vehicles, and may contain formulatoryagents such as suspending, stabilising, preserving and/or dispersingagents. Alternatively, the active ingredient may be in powder form forconstitution with a suitable vehicle, e.g. sterile pyrogen-free water,before use. For particle mediated administration the compounds offormula (1) may be coated on particles such as microscopic goldparticles.

In addition to the formulations described above, the compounds offormula (1) may also be formulated as a depot preparation. Such longacting formulations may be administered by implantation or byintramuscular injection.

For nasal administration or administration by inhalation, the compoundsfor use according to the present invention are conveniently delivered inthe form of an aerosol spray presentation for pressurised packs or anebuliser, with the use of suitable propellant, e.g.dichlorodifluoromethane, trichloro-fluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas ormixture of gases.

For vaginal or rectal administration the compounds of formula (1) may beformulated as a suppository. These formulations may be prepared bymixing the active ingredient with a suitable non-irritating excipientwhich is a solid at room temperature but liquid at the body temperature.Such materials include for example cocoa butter and polyethyleneglycols.

The compositions may, if desired, be presented in a pack or dispenserdevice which may contain one or more unit dosage forms containing theactive ingredient. The pack or dispensing device may be accompanied byinstructions for administration.

The quantity of a compound of the invention required for the prophylaxisor treatment of a particular condition will vary depending on thecompound chosen, and the condition of the patient to be treated. Ingeneral, however, daily dosages may range from around 100 ng/kg to 100mg/kg e.g. around 0.01 mg/kg to 40 mg/kg body weight for oral or buccaladministration, from around 10 ng/kg to 50 mg/kg body weight forparenteral administration and around 0.05 mg to around 1000 mg e.g.around 0.5 mg to around 1000 mg for nasal administration oradministration by inhalation or insufflation.

The compounds of the invention may be prepared by a number of processesas generally described below and more specifically in the Exampleshereinafter. Many of the reactions described are well-known standardsynthetic methods which may be applied to a variety of compounds and assuch can be used not only to generate compounds of the invention, butalso where necessary the intermediates thereto.

In the following process description, the symbols D, E, Alk³, n, m, R¹and R² when used in the formulae depicted are to be understood torepresent those groups described above in relation to formula (1) unlessotherwise indicated. In the reactions described below, it may benecessary to protect reactive functional groups, for example hydroxy,amino, thio or carboxy groups, where these are desired in the finalproduct, to avoid their unwanted participation in the reactions.Conventional protecting groups may be used in accordance with standardpractice [see, for example, Green, T. W. in “Protective Groups inOrganic Synthesis”, John Wiley and Sons, (1999) and the examplesherein]. In some instances, deprotection may be the final step in thesynthesis of a compound of formula (1) and the processes according tothe invention described hereinafter are to be understood to extend tosuch removal of protecting groups.

Thus according to a further aspect of the invention, a compound offormula (1) may be prepared from an amine of general formula (i) usingthe general method as shown in Scheme A:

Thus, an amine of formula (i) may be reacted with an isocyanate ofgeneral formula (ii) in the presence of a base, such as an amine basee.g. triethylamine or diisopropylethylamine in a solvent such as ahalogenated hydrocarbon e.g. dichloromethane at around ambienttemperature to give a compound of general formula (1) where R¹ is ahydrogen atom.

The amine of general formula (i) may be prepared using the generalScheme B as shown below:

Thus, an amine of general formula (iii) where P is a suitable protectinggroup e.g. tert-butoxycarbonyl, may be reacted with a compound offormula E-Alk³-X (v), wherein X is a suitable leaving group (e.g. ahalogen, such as chlorine or bromine, or an arylsulfonyloxy group, suchas p-toluene sulfonate) to give a compound of general formula (vi). Thereaction may be performed in the presence of a base, such as potassiumcarbonate in, for example, refluxing acetonitrile orN,N-dimethylformamide at around ambient temperature.

Alternatively the protected amine of general formula (vi) may beprepared by reductive alkylation of a compound of formula (iii) with acompound of formula E-Alk^(3b) (iv), wherein Alk^(3b) is a suitableprecursor to Alk³, for example Alk^(3b) contains a reactive group, suchas a reactive carbonyl. This reaction may be achieved using methodsknown to those skilled in the art. For example, when Alk^(3b) is analdehyde, appropriate conditions may include the use of a suitableborohydride as reductant, for example sodium triacetoxyborohydride orsodium cyanoborohydride, in a solvent such as a halogenated hydrocarbon,e.g. dichloromethane, or an alcohol, e.g. methanol or ethanol, wherenecessary in the presence of an acid such as acetic acid at aroundambient temperature. A dehydrating agent, such as an orthoformate e.g.triethylorthoformate or trimethylorthoformate may also be employed inthe reaction.

The compounds of formula (v) may be prepared from an alcohol of generalformula E-Alk³-OH (vii) using standard methodology known to thoseskilled in the art. For example, when X is an arylsulfonate ester, thismay be prepared by reaction of the alcohol (vii) with p-toluenesulfonylchloride in the presence of an amine base, e.g. triethylamine in anappropriate solvent, such as dichloromethane or tetrahydrofuran.

The compounds of formula (vii) may also be used to prepare the compoundsof formula (iv) using standard oxidising conditions such as thosedescribed herein.

The intermediate compound of formula (vi) may be deprotected usingstandard methodology, for example by treatment with an acid such astrifluoroacetic acid or hydrochloric acid, to give an amine startingmaterial of general formula (i) wherein R² is a hydrogen atom. This maybe alkylated using standard techniques known to those skilled in theart, such as those methods as described herein, to give an amine offormula (vi) wherein R² is an alkyl group.

A compound of formula (1) may also be prepared by the general method asshown in Scheme C:

Thus an isocyanate of formula (viii) may be reacted with an amine offormula (ix) in the presence of a base, such as an amine base e.g.triethylamine or diisopropylethylamine in a solvent such as ahalogenated hydrocarbon e.g. dichloromethane to give a compound ofgeneral formula (1) where R² is a hydrogen atom.

It will be further appreciated that the order of reactions in which acompound of formula (1) is prepared may be varied. Thus, for example, anamine of formula (x):

where P is as defined above, may be reacted with an isocyanate ofgeneral formula (ii) using the reactions just described to yield acompound of formula (xi). Alternatively an amine of formula (x), whereinR² is a hydrogen atom, may be converted into an isocyanate, for example,using an appropriate reagent such as triphosgene or trichloromethylchloroformate using conditions known to those skilled in the art, andsubsequently reacted with an amine of formula (ix). The resulting ureaof formula (xi):

may be deprotected using methods known to those skilled and reacted witha compound of general formula (iv) or (v) using standard techniques,such as the methods described herein.

The synthesis of compounds of formula (1) may be amenable to highthroughput methods, such as combinatorial or parallel synthesistechniques familiar to those skilled in the art.

Intermediates of formulae (i)-(xi) and any other intermediates requiredto obtain compounds of formula (1), if not available commercially, maybe prepared by methods known to those skilled in the art followingprocedures set forth in references such as Rodd's Chemistry of CarbonCompounds, Volumes 1-15 and Supplementals (Elsevier Science Publishers,1989), Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-19(John Wiley and Sons, 1999), Comprehensive Heterocyclic Chemistry, Ed.Katritzky et al, Volumes 1-8, 1984 and Volumes 1-11, 1994 (Pergamon),Comprehensive Organic Functional Group Transformations, Ed. Katritzky etal, Volumes 1-7, 1995 Pergamon), Comprehensive Organic Synthesis, Ed.Trost and Flemming, Volumes 1-9, (Pergamon, 1991), Encyclopedia ofReagents for Organic Synthesis Ed. Paquette, Volumes 1-8 (John Wiley andSons, 1995), Larock's Comprehensive Organic Transformations (VCHPublishers Inc., 1989) and March's Advanced Organic Chemistry (JohnWiley and Sons, 1992).

For example, an isocyanate of general formula (ii) or (viii) may beprepared by reacting an appropriate amine precursor with an appropriatereagent such as triphosgene or trichloromethyl chloroformate usingconditions known to those skilled in the art.

The amine precursors of formulae (i), (iii), (ix) or (x) when notcommercially available may be prepared using well-known literaturemethods.

It will be appreciated that compounds of formula (1), or any precedingintermediates may be further derivatised by one or more standardsynthetic methods employing substitution, oxidation, reduction orcleavage reactions. Particular substitution approaches includeconventional alkylation, arylation, heteroarylation, acylation,thioacylation, halogenation, sulphonylation, nitration, formylation andcoupling procedures. It will be appreciated that these methods may alsobe used to obtain or modify other compounds of formula (1), whereappropriate functional groups exist in these compounds.

For example, ester groups may be converted to the corresponding acid[—CO₂H] by acid- or base-catalysed hydrolysis depending on the nature ofthe ester Acid- or base-catalysed hydrolysis may be achieved for exampleby treatment with an organic or inorganic acid, e.g. trifluoroaceticacid in an aqueous solvent or a mineral acid such as hydrochloric acidin a solvent such as dioxan or an alkali metal hydroxide, e.g. lithiumhydroxide in an aqueous alcohol, e.g. aqueous methanol. Similarly anacid [—CO₂H] may be prepared by hydrolysis of the corresponding nitrile[—CN], using for example a base such as sodium hydroxide in a refluxingalcoholic solvent, such as ethanol.

In another example, —OH groups may be generated from a correspondingester or aldehyde [—CHO] by reduction, using for example a complex metalhydride such as lithium aluminium hydride or sodium borohydride in asolvent such as methanol. Alternatively an alcohol may be prepared byreduction of the corresponding acid [—CO₂H], using for example lithiumaluminium hydride in a solvent such as tetrahydrofuran.

Alcohol groups may be converted into leaving groups, such as an halogenatoms or sulfonyloxy groups such as an alkylsulfonyloxy, e.g.trifluoromethylsulfonyloxy or arylsulfonyloxy, e.g. p-toluenesulfonyloxygroup using conditions known to the skilled artisan. For example, analcohol may be reacted with thionyl chloride in a halogenatedhydrocarbon e.g., dichloromethane to yield the corresponding chloride. Abase e.g., triethylamine may also be used in the reaction.

Aldehyde [—CHO] groups may be obtained by oxidation of a correspondingalcohol using well known conditions. For example using an oxidisingagent such as a periodinane e.g Dess Martin, in a solvent such as ahalogenated hydrocarbon, e.g. dichloromethane. An alternative oxidationmay be suitably activating dimethyl sulfoxide using for example, oxalylchloride, followed by addition of an alcohol, and subsequent quenchingof the reaction by the addition of an amine base, such as triethylamine.Suitable conditions for this reaction may be using an appropriatesolvent, for example, a halogenated hydrocarbon, e.g. dichloromethane at−78° C. followed by subsequent warming to room temperature.

α,β-Unsaturated aldehydes, for example, of formula OHCE, where E iscycloalkenyl, may be prepared by hydrolysis of a corresponding allylicnitro compound. This may be achieved, for example, by treatment of theallylic nitro compound with a base, such as sodium methoxide orpotassium tert-butoxide, followed by addition of a buffered aqueoustitanium trichloride solution. The allylic nitro compound may beprepared by nucleophilic addition of nitromethane to the correspondingketone, followed by elimination of water. Suitable conditions for thisreaction may be refluxing in toluene under Dean Stark conditions, in thepresence of an amine base, such as N,N-dimethylethylene diamine. It willbe appreciated that these aldehydes may be used in reductive alkylationsto give compounds of formula (1) where Alk³ is —CH₂— using theconditions described herein.

In a further example primary amine (—NH₂) or secondary amine (—NH—)groups may be alkylated using a reductive alkylation process employingan aldehyde and a borohydride, for example sodium triacetoxyborohyrideor sodium cyanoborohydride, in a solvent such as a halogenatedhydrocarbon, e.g. dichloromethane, a ketone such as acetone, or analcohol, e.g. ethanol, where necessary in the presence of an acid suchas acetic acid at around ambient temperature.

In a further example, amine [—NH₂] groups may be obtained by hydrolysisfrom a corresponding imide by reaction with hydrazine in a solvent suchas an alcohol, e.g. ethanol at ambient temperature.

In another example, a nitro [—NO₂] group may be reduced to an amine[—NH₂], for example by catalytic hydrogenation using for examplehydrogen in the presence of a metal catalyst, for example palladium on asupport such as carbon in a solvent such as an ether, e.g.tetrahydrofuran or an alcohol e.g. methanol, or by chemical reductionusing for example a metal, e.g. tin or iron, in the presence of an acidsuch as hydrochloric acid.

In a further example amine (—CH₂NH₂) groups may be obtained by reductionof nitriles (—CN), for example by catalytic hydrogenation using forexample hydrogen in the presence of a metal catalyst, for examplepalladium on a support such as carbon, or Raney® nickel, in a solventsuch as an ether e.g. a cyclic ether such as tetrahydrofuran or analcohol, e.g. methanol or ethanol, optionally in the presence of ammoniasolution at a temperature from ambient to the reflux temperature, or bychemical reduction using for example a metal hydride, e.g. lithiumaluminium hydride, in a solvent such as an ether, e.g. a cyclic ethersuch as tetrahydrofuran, at a temperature from 0° C. to the refluxtemperature.

Aromatic halogen substituents in the compounds may be subjected tohalogen-metal exchange with a base, for example a lithium base such asn-butyl or t-butyl lithium, optionally at a low temperature, e.g. around−78° C., in a solvent such as tetrahydrofuran and then quenched with anelectrophile to introduce a desired substituent. Thus, for example, aformyl group may be introduced by using dimethylformamide as theelectrophile; a thiomethyl group may be introduced by usingdimethyldisulphide as the electrophile.

N-oxides of compounds of formula (1) may be prepared for example byoxidation of the corresponding nitrogen base using an oxidising agentsuch as hydrogen peroxide in the presence of an acid such as aceticacid, at an elevated temperature, for example around 70° C. to 80° C.,or alternatively by reaction with a peracid such as peracetic acid in asolvent, e.g. dichloromethane, at ambient temperature.

Salts of compounds of formula (1) may be prepared by reaction of acompound of formula (1) with an appropriate base or acid in a suitablesolvent or mixture of solvents e.g. an organic solvent such as an ethere.g. diethylether, or an alcohol, e.g. ethanol or an aqueous solventusing conventional procedures. Salts of compounds of formula (1) may beexchanged for other salts by use of conventional ion-exchangechromatography procedures.

Where it is desired to obtain a particular enantiomer of a compound offormula (1) this may be produced from a corresponding mixture ofenantiomers using any suitable conventional procedure for resolvingenantiomers.

Thus for example diastereomeric derivatives, e.g. salts, may be producedby reaction of a mixture of enantiomers of formula (1) e.g. a racemate,and an appropriate chiral compound, e.g. a chiral base. Thediastereomers may then be separated by any convenient means, for exampleby crystallisation and the desired enantiomer recovered, e.g. bytreatment with an acid in the instance where the diastereomer is a salt.

In another resolution process a racemate of formula (1) may be separatedusing chiral High Performance Liquid Chromatography. Alternatively, ifdesired a particular enantiomer may be obtained by using an appropriatechiral intermediate in one of the processes described above.

Chromatography, recrystallisation and other conventional separationprocedures may also be used with intermediates or final products whereit is desired to obtain a particular geometric isomer of the invention.

The following Examples illustrate the invention. All temperatures are in° C. Where experimental detail is not given for the preparation of areagent it is either commercially available, or it is known in theliterature, for which the CAS number is quoted. The compounds are namedwith the aid of Beilstein Autonom supplied -by MDL Information SystemsGmbH, Theodor-Heuss-Allee 108, D-60486-Frankfurt, Germany. ¹H NMRspectra were obtained at 300 MHz or 400 MHz unless otherwise indicated.

The following LCMS conditions were used to acquire the retention timesas reported herein:

LCMS Conditions:

HP1100 (Diode Array) linked to a Finnigan LcQ Duo Mass Spectrometer.Column: Luna C18(2) 100 × 4.6 mm, 5 μn particle size Analytical columnColumn Temp: 35° C. Mobile Phase: A: 0.08% formic acid in H₂O B: 0.08%formic acid in MeCN Flow rate: 3 ml/min Gradient: Time (mins): %Composition B: 0.0 95.0 4.40 5.0 5.30 5.0 5.32 95.0 6.50 95.0 Run time:6.50 mins Typical Injection Vol: 10 μl Detector Wavelength: 210 nm

Preparative LC Conditions (HPLC):

MassLynx Setup Column: Luna C18(2) 100 × 21.2 mm, 5 μn particle sizePREP Column Temp: Ambient Mobile Phase: A: Water + 0.08% formic acid B:Acetonitrile + 0.08% formic acid Gradient: Variable - depends onretention of sample in LCMS screen Run Time: 10 mins Flow rate: 20ml/min Typical Injection Vol: 0.8 ml of 20 mg/ml solution DetectorWavelength: 210 and 254 nm Abbreviations used: DCM - DichloromethaneTHF - Tetrahydrofuran MeOH - Methanol EtOAc - Ethyl acetate TFA -Trifluoroacetic acid BOC - tert-butoxycarbonyl CDCl₃ - Deuteratedchloroform DMSO-d₆ - Deuterated dimethylsulfoxide Methanol-d₄ -Deuterated methanol DMF - N,N-dimethylformamide

Intermediate 1 4-(Boc-amino)-1-cycloocten-1-yl piperidine

Piperidin-4-yl-carbamic acid tert-butyl ester hydrochloride [CAS No.73874-95-0] (2 g) was dissolved in DCM (20 ml) and triethylamine (2 g)and triethylorthoformate (5 ml) were added. 1-Cyclooctene carboxaldehyde[CAS No. 6038-12-6] (2 g) was added and the mixture stirred for 30 min,then sodium triacetoxyborohydride (4 g) was added and the mixturestirred overnight at room temperature. The solution was washed withsodium bicarbonate (20 ml), dried (MgSO₄) and evaporated to give thetitle compound as a beige solid (2.6 g). TLC R_(f) 0.25 (5% MeOH/DCM)

Intermediate 2 was prepared in a similar manner to Intermediate 1:

Intermediate 2[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-carbamicacid tert-butyl ester

From piperidin-4-yl-carbamic acid tert-butyl ester hydrochloride [CASNo. 73874-95-0] (1.63 g) and6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-carbaldehyde [CAS No. 18486-69-6](1.26 ml) to give a light yellow oil (2.91 g). Purification by columnchromatography (5% MeOH/DCM) afforded the title compound as colourlesssolid (1.75 g). Retention time 2.25 minutes. M+H 335

Intermediate 3 4-Amino-1-cycloocten-1-ylpiperidine

TFA (10 ml) was added to a solution of Intermediate 1 (2.6 g) in DCM (30ml) at room temperature. The solution was stirred for 2 h, and thenevaporated in vacuo and the residue dissolved in water (30 ml) andwashed with ether (20 ml). The aqueous layer was basified with sodiumhydroxide pellets and extracted with DCM (2×20 ml). The solvent waswashed with water (20 ml) and brine (20 ml), dried (MgSO₄) andevaporated to give the title compound as a pale yellow oil. TLC R_(f)0.22 (10% MeOH/DCM 1% NH₄OH).

Intermediate 4 was prepared in a similar manner to Intermediate 3:

Intermediate 41-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-ylamine

From Intermediate 2 (3 g.) to give the title compound as an orange oil(2.4 g). TLC R_(f) 0.30 (10% MeOH/DCM 1% NH₄OH).

Intermediate 5[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]methyl-amine

Intermediate 2 (368 mg) was dissolved in THF (5.0 ml) and cooled to 0°C. LiAlH₄ (1.0 M, 14 ml) solution in THF was added and the reaction wasstirred overnight at room temperature. Isopropanol (about 5 ml) wascarefully added followed by H₂O (0.156 ml), 15% NaOH (0.156 ml) and H₂O(0.469 ml). After stirring for 1 hr. the grey precipitate was filteredoff and the filtrate concentrated to give the title compound as a yellowoil (250 mg). Retention time 1.10 minutes. M+H 249

Intermediate 6N-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-acetamide

Intermediate 4 (992 mg) was dissolved in DCM (25 ml) anddiisopropylethylamine (0.697 ml) was added. The reaction mixture wascooled to 0° C. and acetyl chloride (0.213 ml) was added drop wise.Stirring was continued overnight at room temperature. The reactionmixture was extracted with sodium bicarbonate (2×20 ml), brine (20 ml),dried (MgSO₄) and evaporated to give the title compound as a white solid(0.85 g). Retention time 1.64 minutes. M+H 277

Intermediate 7[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]ethyl-amine

Intermediate 6 (850 mg) was dissolved in THF (20.0 ml) and cooled to 0°C. LiAIH₄ (1.0 M, 10 ml) solution in THF was added and the reaction wasstirred overnight at room temperature. Isopropanol (about 5 ml) wascarefully added followed by H₂O (0.380 ml), 15% NaOH (0.380 ml) and H₂O(1.14 ml). After stirring for 1 hr. the grey precipitate was filteredoff and the filtrate concentrated to give the title compound as a yellowoil (590 mg). Retention time 1.05 minutes. M+H 263

Intermediate 8 1-Naphthalen-2-yl-3-piperidin-4-yl-urea hydrochloride

2-Naphthyl isocyanate (432 mg) was added to a solution ofboc-(4-amino)-piperidine hydrochloride in anhydrous DCM. Triethylamine(360 μl) was added and the reaction mixture was stirred for 17 h at roomtemperature. The reaction mixture was washed with 0.5N HCl, thensaturated aqueous NaHCO₃ solution, dried (MgSO₄) and concentrated invacuo to yield 4-(3-naphthalen-2-yl-ureido)-piperidine-1-carboxylic acidtert-butyl ester as an off-white powder.

To a solution of this product in methanol (14 ml) was added a 1Msolution of HCl in diethyl ether (10 ml) and the reaction mixture wasstirred for 18 h at room temperature. The solvent was removed in vacuoand the residue was triturated with diethyl ether and dried in vacuo toafford the title compound as a beige powder (674 mg). LCMS m/z 270 (MH⁺)observed.

EXAMPLE 1 N-2-Naphthyl-N′-(cyclooctene-1-yl)methylpiperidine urea

2-Naphthyl isocyanate (1 g) was added to a solution of tert-butyl4-aminopiperidine-1-carboxylate (CAS No. 73874-95-0) (1.2 g) in DCM andthe solution was stirred for 24 h at room temperature. The mixture wasevaporated in vacuo and the solid product triturated with ether. Theresidue was dissolved in DCM (50 ml) and TFA (10 ml) was added. Thesolution was stirred for 3 h, then evaporated in vacuo and the residuecrystallised from methanol (5 ml)/diethyl ether (20 ml). The solidproduct was dissolved in DCM (50 ml) and trimethyl orthoformate (10 ml)and triethylamine (1.5 ml) were added, followed by 1-cyclooctenecarboxaldehyde (1.2 g). The mixture was stirred for 1 h, then sodiumtriacetoxyborohydride (3 g) was added. The resulting suspension wasstirred overnight, then the mixture was filtered through Celite®, washedwith water (20 ml) and sodium bicarbonate (20 ml) solution andevaporated. The residue was crystallised from EtOAc/hexanes to give thetitle compound as colourless solid (0.85 g). TLC R_(f) 0.35 (10%MeOH/DCM). MS 391 (M⁺)

EXAMPLE 21-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea

3,4-Dichlorophenyl isocyanate (100 mg) was added to a solution ofIntermediate 3 (100 mg) in DCM (10 ml). Triethylamine (100 mg) was addedand the solution was stirred overnight, washed with water (10 ml) andbrine (10 ml), then evaporated to dryness and triturated with ether togive the title compound as colourless solid (0.15 g). Retention time2.39 minutes. TLC R_(f) 0.40 (10% MeOH/DCM). MS 410 (M+1)

EXAMPLE 31-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(4-trifluoromethylphenyl)urea

4-Trifluoromethylphenyl isocyanate (100 mg) was added to a solution ofIntermediate 3 (100 mg) in DCM (10 ml). Triethylamine was added and themixture stirred overnight, washed with water (10 ml) and brine (10 ml),dried (MgSO₄) and evaporated and the residue triturated with ether togive the title compound as colourless solid (0.12 g). Retention time2.36 minutes. TLC R_(f) 0.29 (10% MeOH/DCM). MS 410 (M+1)

The compounds of :Examples 4-11 were prepared in a similar manner to thecompound of Example 3 using Intermediate 3 and the appropriatecommercially available isocyanate:

EXAMPLE 41-(3-Cyanophenyl)-3-[1-((E)-1-cyclooct-1-enyl)methylpiperidin-4-yl]urea

From 3-cyanophenyl isocyanate. Yield 7.5 mg.

Retention time 2.06 minutes. TLC R_(f) 0.30 (10% MeOH/DCM). MS 367 M+1

EXAMPLE 51-Benzo[1,3]dioxol-5-yl-3-[1-((E)-1-cyclooct-1-enyl)methylpiperidin-4-yl]-urea

From 3,4-methylenedioxyphenyl isocyanate. Yield 15 mg.

Retention time 2.01 minutes. TLC R_(f) 0.26 (10% MeOH/DCM). MS 386 M+1

EXAMPLE 61-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(4-phenoxyphenyl)-urea

From 4-phenoxyphenyl isocyanate. Yield 9 mg.

Retention time 2.43 minutes. TLC R_(f) 0.37 (10% MeOH/DCM). MS 434 (M+1)

EXAMPLE 71-Biphenyl-4-yl-3-[1-((E)-1-cyclooct-1-enyl)methylpiperidin-4-yl]-urea

From biphenyl isocyanate. Yield 8.5 mg.

Retention time 2.45 minutes. TLC R_(f) 0.37 (10% MeOH/DCM). MS 418 (M+1)

EXAMPLE 81-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(2,2,4,4-tetrafluoro-4H-benzo[1,3]dioxin-6-yl)urea

From 6-isocyano-2,2,4,4-tetrafluoro-1,3-benzodioxane. Yield 22 mg.

Retention time 2.53 minutes. TLC R_(f) 0.40 (10% MeOH/DCM). MS 472 (M+1)

EXAMPLE 91-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl-3-indan-5-ylurea

From 5-indanyl isocyanate. Yield 11 mg.

Retention time 2.27 minutes. TLC R_(f) 0.33 (10% MeOH/DCM). MS 382 (M+1)

EXAMPLE 10

1-(4-Cyanophenyl)-3-[1-((E)-1-cyclooct-1-enyl)methylpiperidin-4-yl]urea

From 4-cyanophenyl isocyanate. Yield 12 mg.

Retention time 2.06 minutes. TLC R_(f) 0.25 (10% MeOH/DCM). MS 367 (M+1)

EXAMPLE 111-[-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-naphthalen-2-ylurea

Prepared from Intermediate 4 (100 mg) and 2-naphthyl isocyanate (100 mg)to afford the title compound as a white solid 0.13 g. TLC R_(f) 0.37(10% MeOH/DCM). MS 404 (M+1)

EXAMPLE 121-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-methyl-3-(3-trifluoromethylphenyl)urea

To trifluorometatolyl isocyanate (38 mg) was added 1.0 ml of a 0.2 Msolution of Intermediate 5 in dry DCM. The title compound was obtainedby concentration of the reaction mixture and purification by prep HPLC.(32 mg). Retention time 2.46 minutes. M+H 436

Examples 13-47 were prepared in a similar manner to the compound ofExample 12 from commercially available isocyanates using solution phaseparallel synthesis methodology:

EXAMPLE 131-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-methyl-3-naphthalen-2-ylurea

From 2-naphthyl isocyanate (34 mg) and 1.0 ml of a 0.2 M solution ofIntermediate 5 in dry DCM. Yield 21 mg. Retention time 2.39 minutes. M+H418

EXAMPLE 141-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-methyl-3-(3-methylsulfanylphenyl)urea

From 3-(methylthio)phenyl isocyanate (33 mg) and 1.0 ml of a 0.2 Msolution of Intermediate 5 in dry DCM. Yield 45 mg. Retention time 2.29minutes. M+H 414

EXAMPLE 151-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(3-ethylphenyl)-1-methylurea

From 3-ethylphenyl isocyanate (29 mg) and 1.0 ml of a 0.2 M solution ofIntermediate 5 in dry DCM. Yield 40 mg. Retention time 2.36 minutes. M+H396

EXAMPLE 161-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-methyl-3-(5-phenylthiophen-2-yl)urea

From 5-phenyl-2-thienyl isocyanate (40 mg) and 1.0 ml of a 0.2 Msolution of Intermediate 5 in dry DCM. Yield 42 mg. Retention time 2.54minutes. M+H 450

EXAMPLE 171-(1-Adamantan-1-ylmethylpiperidin-4-yl)-3-(3-trifluoromethylphenyl)-urea

From trifluorometatolyl isocyanate (76 mg) and 2.0 ml of a 0.2 Msolution of 1-adamantan-1-ylmethylpiperidin-4-ylamine [CAS No.64306-80-5] in dry DCM. Yield 45 mg. Retention time 2.38 minutes. M+H436

EXAMPLE 181-(1-Adamantan-1-ylmethylpiperidin-4-yl)-3-naphthalen-2-ylurea

From 2-naphthyl isocyanate (68 mg) and 2.0 ml of a 0.2 M solution of1-adamantan-1-ylmethylpiperidin-4-ylamine [CAS No. 64306-80-5] in dryDCM. Yield 29 mg. Retention time 2.38 minutes. M+H 418

EXAMPLE 191-(1-Adamantan-1-ylmethylpiperidin-4-yl)-3-(3-methylsulfanylphenyl)-urea

From 3-(methylthio)phenyl isocyanate (66 mg) and 2.0 ml of a 0.2 Msolution of 1-adamantan-1-ylmethyl-piperidin-4-ylamine [CAS No.64306-80-5] in dry DCM. Yield 19 mg. Retention time 2.31 minutes. M+H414

EXAMPLE 201-(1-Adamantan-1-ylmethylpiperidin-4-yl)-3-(3-ethylphenyl)urea

From 3-ethylphenyl isocyanate (58 mg) and 2.0 ml of a 0.2 M solution of1-adamantan-1-ylmethylpiperidin-4-ylamine [CAS No. 64306-80-5] in dryDCM. Yield 9 mg. Retention time 2.38 minutes. M+H 396

EXAMPLE 211-(1-Adamantan-1-ylmethylpiperidin-4-yl)-3-(5-phenylthiophen-2-yl)urea

From 5-phenyl-2-thienyl isocyanate (80 mg) and 2.0 ml of a 0.2 Msolution of 1-adamantan-1-ylmethylpiperidin-4-ylamine [CAS No.64306-80-5] in dry DCM. Yield 20 mg. Retention time 2.56 minutes. M+H450

EXAMPLE 221-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-ethyl-3-(3-trifluoromethylphenyl)urea

From trifluorometatolyl isocyanate (14 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 7 in dry DCM. Yield 7 mg. Retention time 2.58minutes. M+H 450

EXAMPLE 231-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-ethyl-3-naphthalen-2-ylurea

From 2-naphthyl isocyanate (13 mg) and 1.0 ml of a 0.075 M solution ofIntermediate 7 in dry DCM. Yield 13 mg. Retention time 2.54 minutes. M+H432

EXAMPLE 241-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-ethyl-3-(3-methylsulfanylphenyl)urea

From 3-(methylthio)phenyl isocyanate (12 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 7 in dry DCM. Yield 13 mg. Retention time 2.40minutes. M+H 428

EXAMPLE 251-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-ethyl-3-(3-ethylphenyl)urea

From 3-ethylphenyl isocyanate (11 mg) and 1.0 ml of a 0.075 M solutionof Intermediate 7 in dry DCM. Yield 12 mg. Retention time 2.49 minutes.M+H 410

EXAMPLE 261-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-1-ethyl-3-(5-phenylthiophen-2-yl)urea

From 5-phenyl-2-thienyl isocyanate (15 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 7 in dry DCM. Yield 10 mg. Retention time 2.70minutes. M+H 464

EXAMPLE 271-[1-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(3-ethylphenyl)urea

From 3-ethylphenyl isocyanate (300 mg) and Intermediate 4 (614 mg).Yield 600 mg. Retention time 2.38 minutes. M+H 382

EXAMPLE 28′1-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(3-methylsulfanylphenyl)urea

From 3-(methylthio)phenyl isocyanate (12 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 4. Yield 3.42 mg. Retention time 2.24 minutes.M+H 400

EXAMPLE 29′3-{3-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)-piperidin-4-yl]ureido}benzoicacid methyl ester

From 3-(methoxycarbonyl)phenyl isocyanate (13 mg) and 1.0 ml of a 0.075M solution of Intermediate 4. Yield 3.05 mg. Retention time 2.15minutes. M+H 412

EXAMPLE 30 ′1-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1

hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(4-isopropylphenyl)urea

From 4-isopropylphenyl isocyanate (12 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 4. Yield 4.74 mg. Retention time 2.39 minutes.M+H 396

EXAMPLE 31′1-(4-tert-Butylphenyl)-3-[1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea

From 4-tert-butylphenyl isocyanate (13 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 4. Yield 4.86 mg. Retention time 2.51 minutes.M+H 410

EXAMPLE 32′1-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(5-phenylthiophen-2-yl)urea

From 5-phenyl-2-thienyl isocyanate (15 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 4. Yield 4.11 mg. Retention time 2.49 minutes.M+H 436

EXAMPLE 33′1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin4-yl]-3-(2,6-dichloropyridin-4-yl)urea

From 2,6-dichloro-4-pyridyl isocyanate (14 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 3. Yield 4.10 mg. Retention time 2.20 minutes.M+H 410

EXAMPLE 34′1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(5-phenylthiophen-2-yl)urea

From 5-phenyl-2-thienyl isocyanate (15 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 3. Yield 7.26 mg. Retention time 2.44 minutes.M+H 424

EXAMPLE 35′1-(3-Bromophenyl)-3-[1-((1R,5S)-6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea

From 3-bromophenyl isocyanate (15 mg) and 1.0 ml of a 0.075 M solutionof Intermediate 4. Yield 3.75 mg. Retention time 2.30 minutes. M+H 432

EXAMPLE 36′1-(2,3-Dichlorophenyl)-3-[1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-y]urea

From 2,3 dichlorophenyl isocyanate (14 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 4. Yield 5.45 mg. Retention time 2.37 minutes.M+H 422

EXAMPLE 37′1-(3-Chlorophenyl)-3-[1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea

From 3-chlorophenyl isocyanate (12 mg) and 1.0 ml of a 0.075 M solutionof Intermediate 4. Yield 4.77 mg. Retention time 2.30 minutes. M+H 388

EXAMPLE 38′1-(4-Chlorophenyl)-3-[1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea

From 4-chlorophenyl isocyanate (12 mg) and 1.0 ml of a 0.075 M solutionof Intermediate 4. Yield 3.92 mg. Retention time 2.28 minutes. M+H 388

EXAMPLE 39′1-(4-Chloro-3-trifluoromethylphenyl)-3-[1-((1R,5S)-6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea

From 4-chloro-3-trifluoromethylphenyl isocyanate (17 mg) and 1.0 ml of a0.075 M solution of Intermediate 4. Yield 4.29 mg. Retention time 2.55minutes. M+H 456

EXAMPLE 40′1-(3,5-Bistrifluoromethylphenyl)-3-[1-((1R,5S)-6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]urea

From 3,5-bis(trifluoromethyl)phenyl isocyanate (19 mg) and 1.0 ml of a0.075 M solution of Intermediate 4. Yield 3.85 mg. Retention time 2.70minutes. M+H 490

EXAMPLE 41′1-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(3-trifluoromethylphenyl)urea

From 3-trifluoromethylphenyl isocyanate (14 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 4. Yield 4.59 mg. Retention time 2.38 minutes.M+H 422

EXAMPLE 42′1-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(3-fluorophenyl)urea

From 3-fluorophenyl isocyanate (10 mg) and 1.0 ml of a 0.075 M solutionof Intermediate 4. Yield 3.66 mg. Retention time 2.18 minutes. M+H 372

EXAMPLE 43′1-[1-((1R5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-ylmethyl)piperidin-4-yl]-3-(3-methoxyphenyl)urea

From 3-methoxyphenyl isocyanate (11 mg) and 1.0 ml of a 0.075 M solutionof Intermediate 4. Yield 6.60 mg. Retention time 2.12 minutes. M+H 384

EXAMPLE 44′1-(4-Chloro-3-trifluoromethylphenyl)-3-[1-((E)-1-cyclooct-1-enyl)methyl-piperidin-4-yl]urea

From 4-chloro-3-trifluoromethyl-phenyl isocyanate (17 mg) and 1.0 ml ofa 0.075 M solution of Intermediate 3. Yield 9.63 mg. Retention time 2.51minutes. M+H 444

EXAMPLE 45′1-(3,5-Bistrifluoromethylphenyl)-3-[1-((E)-1-cyclooct-1-enyl)methyl-piperidin-4-yl]urea

From 3,5-bis(trifluoromethyl)phenyl isocyanate (19 mg) and 1.0 ml of a0.075 M solution of Intermediate 3. Yield 9.93 mg. Retention time 2.65minutes. M+H 478

EXAMPLE 46′1-[1-((E)-1-Cyclooct-1-enyl)methylpiperdin-4-yl]-3-(3-ethylphenyl)urea

From 3-ethylphenyl isocyanate (11 mg) and 1.0 ml of a 0.075 M solutionof Intermediate 3. Yield 8.37 mg. Retention time 2.27 minutes. M+H 370

EXAMPLE 47′1-(3-Chloro-4-methylphenyl)-3-[1-((E)-1-cyclooct-1-enyl)methyl-piperidin-4-yl]urea

From 3-chloro-4-methylphenyl isocyanate (13 mg) and 1.0 ml of a 0.075 Msolution of Intermediate 3. Yield 2.23 mg. Retention time 2.35 minutes.M+H 390

EXAMPLE 48 1-(1-Cyclooctylmethyl-piperidin-4-yl)-3-naphthalen-2-yl-urea

Toluene-4-sulfonic acid cyclooctylmethyl ester (CAS No 16472-97-2) (85mg) and potassium carbonate (120 mg) were added to a solution ofIntermediate 8 (85 mg) in anhydrous DMF (5 ml). The reaction mixture wasstirred for 17 h at room temperature under a nitrogen atmosphere, thenpartitioned between water (25 ml) and dichloromethane (25 ml). Theorganic phase was dried (MgSO₄) and concentrated in vacuo. The residuewas triturated with diethyl ether to afford the title compound as awhite solid (27 mg). TLC R_(f) 0.42 (10% methanol in dichloromethane).LCMS m/z 394 (MH⁺) observed.

EXAMPLE 491-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-3-ylmethyl)piperidin-4-yl]-3-quinolin-6-ylurea

To a cooled solution (−78° C.) of triphosgene (50 mg) in DCM (1 ml) wasadded a solution of intermediate 4 (117 mg; 0.5 mmol) in DCM (2.0 ml).After stirring for 1 hour a solution of 6-aminoquinoline (72 mg; 0.5mmol) and diisopropylethylamine (87 ml) in DCM (1.5 ml) was added andstirring was continued for 18 hours. The reaction mixture was dilutedwith DCM (50 ml) and washed with aqueous sodium bicarbonate solution (50ml), dried and evaporated. Purification by preparative HPLC afforded thetitle compound (55 mg).

Retention time 1.61 minutes. M+H 405

The compound of Example 50 was prepared in a similar manner to thecompound of Example 49:

EXAMPLE 503-[1-((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-3-ylmethyl)piperidin-4-yl]-1-(3-ethylphenyl)-1-methylurea

From Intermediate 4 (47 mg; 0.2 mmol) and 3-ethyl-N-methylaniline (27mg; 0.2 mmol; CAS No. 71265-20-8). Yield 15 mg. Retention time 2.38minutes. M+H 396

Biological Assays

The following assays were used to demonstrate the activity andselectivity of compounds according to the invention.

Chemokine Calcium Assay

The following assay may be used for to determine the inhibition ofbinding of a chemokine to its receptor:

CHO cells stably transfected with the human CXCR3 were seeded in a 96well, blackwalled, clear bottomed tissue culture plate and incubatedovernight at 37° C. in the presence of 5% CO₂. The culture medium wasgently removed from the well and replaced with wash buffer (Hank'sBalanced Salts Solution with 0.2% BSA and 20 mM HEPES pH 7.2) containing3 μM Fluo-4 and 0.03% pluronic acid. The plate was incubated at 37° C.for 1-2 hours, gently washed and 100 μl wash buffer added per well.

Test compounds were dissolved in DMSO and further diluted in wash bufferto give a DMSO concentration of 0.8% (reduced to 0.2% when added to theassay plate in the FLIPR™).

The assay was performed using a FLIPR™ (Molecular Devices). Compound wasadded to the assay plate after a 10 second baseline. Diluted humanrecombinant ITAC, IP-10 or MIG was added after a further 2 minutes.Compound activity was calculated as a percentage inhibition of a DMSOsolvent control.

Compounds of the invention, for example, the compounds of the Examples,are able to inhibit the binding of ITAC, IP-10 or MIG to their receptor(CXCR3) with an activity of >50% at 5 μm. In this assay the most activecompounds according to the invention have IC₅₀ values of around 1 μM orbelow.

The above assay can also be used to determine the selectivity of thecompounds according to the invention, by replacement of CXCR3 with analternative chemokine receptor such as CCR3 and the use of a chemokineknown to bind to such a receptor, such as eotaxin.

In this way the compounds of the invention can be shown to be selectiveinhibitors of CXCR3. Thus for example the compounds of the Examples areat least 5 times more selective with respect to CXCR3 than to otherchemokine receptors such as CCR3.

1. A compound of formula (1):

wherein: m and n, which may be the same or different, are each zero orthe integer 1 or 2; Alk³ is a covalent bond or a straight or branchedC₁₋₆ alkylene; R¹ and R², which may be the same or different, is areeach a hydrogen atom or a straight or branched C₁₋₆ alkyl group; D is anoptionally substituted aromatic or heteroaromatic group; E is anoptionally substituted C₇₋₁₀ cycloalkyl, C₇₋₁₀ cycloalkenyl or C₇₋₁₀polycycloaliphatic group; and the salts, solvates, hydrates, tautomersor N-oxides thereof.
 2. A compound according to claim 1 wherein m and n,which may be the same or different, is are each zero or the integer 1.3. A compound according to claim 2 wherein m and n are each theinteger
 1. 4. A compound according to claim 1 wherein Alk³ is a —CH₂—,—CH₂CH₂— or —CH₂CH₂CH₂— chain.
 5. A compound according to claim 4wherein Alk³ is a —CH₂— chain.
 6. A compound according to claim 1wherein R¹ and R², which may be the same or different, are each ahydrogen atom or a methyl group.
 7. A compound according to claim 1wherein D is an optionally substituted phenyl, 1- or 2-naphthyl,pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, benzofuryl, benzothienyl,indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl,quinazolinyl, quinoxalinyl, naphthyridinyl, quinolinyl, isoquinolinyl,pyrrolyl, furyl, thienyl, imidazolyl, N—C₁₋₆alkylimidazolyl, oxazolyl,isoxazolyl, thiazolyl or isothiazolyl group.
 8. A compound according toclaim 7 wherein D is an optionally substituted phenyl, 2-naphthyl orthienyl group.
 9. A compound according to claim 1 wherein E is anoptionally substituted cycloheptyl, cyclooctyl, cyclononyl,cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantyl,bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]heptenyl, bicyclo[3.1.1]heptanylor bicyclo[3.3.1]heptenyl group.
 10. A compound according to claim 9wherein E is a 1-cyclooctenyl, 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl,adamantyl or cyclooctyl group.
 11. A pharmaceutical compositioncomprising a compound according to claim 1 together with one or morepharmaceutically acceptable carriers, excipients or diluents. 12.(canceled)
 13. A method for the treatment of a disease or disorder in amammal in which inappropriate T-cell trafficking plays a role,comprising administering to said mammal a therapeutically effectiveamount of a compound according to claim
 1. 14. A method according toclaim 13 wherein said disease or disorder is selected from the groupconsisting of inflammatory or allergic diseases, autoimmune diseases,graft rejection, and diseases in which undesired inflammatory responsesare to be inhibited.
 15. A method according to claim 14 wherein saiddisease or disorder is an inflammatory or allergic disease.
 16. A methodaccording to claim 15 wherein said inflammatory or allergic disease isselected from the group consisting of systemic anaphylaxis orhypersensitivity responses, drug allergies, insect sting allergies,inflammatory bowel diseases, vaginitis, psoriasis and inflammatorydermatoses, vasculitis, spondyloarthropathies, scleroderma, andrespiratory allergic diseases.
 17. A method according to claim 14wherein said disease or disorder is an autoimmune disease.
 18. A methodaccording to claim 17 wherein said autoimmune disease is selected fromthe group consisting of arthritis, multiple sclerosis, systemic lupuserythematosus, diabetes, and glomerulonephritis.
 19. A method accordingto claim 14 wherein said disease or disorder is graft rejection.
 20. Amethod according to claim 14 wherein said disease or disorder is adisease in which an undesired inflammatory response is to be inhibited.21. A method according to claim 20 wherein said disease is selected fromthe group consisting of atherosclerosis, myositis, neurodegenerativediseases, Alzheimer's disease, encephalitis, meningitis, hepatitis,nephritis, sepsis, sarcoidosis, conjunctivitis, otitis, chronicobstructive pulmonary disease, sinusitis, Behcet's syndrome, Sjorgen'ssyndrome and glomerulonephrites.
 22. A method for inhibiting, in amammal suspected to suffer from a disease or disorder in whichchemokine-mediated cell signaling plays a role, the binding ofchemokines to the CXCR3 receptor, comprising administering to the mammalan effective amount of a compound according to claim 1.